AJP - Endo Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab (July 26, 2005). doi:10.1152/ajpendo.00209.2005
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
289/6/E1044    most recent
00209.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ferone, D.
Right arrow Articles by Barreca, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferone, D.
Right arrow Articles by Barreca, A.
Submitted on May 10, 2005
Accepted on July 21, 2005

Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation

Diego Ferone1*, Marica Arvigo1, Claudia Semino1, Philippe Jaquet2, Alexandru Saveanu2, John E Taylor3, Jacques-Pierre Moreau3, Michael D Culler3, Manuela Albertelli1, Francesco Minuto1, and Antonina Barreca1

1 Department of Endocrinological & Metabolic Sciences and Centre for Excellence for Biomedical Research, University of Genova, Genova, Italy
2 Interactions Cellulaires Neuroendocriniennes, Unite Mixte de Recherche 6544, Centre National de la Recherche Scientifique, Institut Federatif Jean Roche, Faculte de Medecine Nord, Marseille Cedex, France
3 Biomeasure Inc./IPSEN, Milford, Massachusetts, USA

* To whom correspondence should be addressed. E-mail: ferone{at}unige.it.

To study somatostatin/dopamine (SS/D) synergy in a human cell system constitutively expressing SS and D receptors (SSR, DR), we characterized the expression of SSR and DR subtypes in the non-small cell lung cancer line CALU-6 and then we evaluated the effect on cell proliferation of SS/D chimeric molecules (BIM-23A387 and BIM-23A370), which bind with high affinity both sst2 and D2R, and compared the results with those obtained using SS-14 and subtype-selective SS analogs (SSA) and D agonists (DA). Since CALU-6 cells produce IGF and IGFBP peptides, which play a role in the autocrine/paracrine control of cell growth, we also investigated the effects of chimeric compounds on secretion and expression of IGF system components. Relative high levels of sst2, as well as the long isoform of the D2R were detected by real-time RT-PCR and Western blot in CALU-6, together with sst5 and to a lesser extent sst3 and D4R. BIM-23A387 and BIM-23A370 significantly inhibited growth of CALU-6, whereas IGF-IGFBP secretion or expression were unaffected, suggesting a direct inhibitory effect. The inhibition of cell growth, measured by both 3H-thymidine incorporation and cell count, was significantly lower when individual SSA and DA control peptides, or subtype-specific SSA and DA were tested. BIM-23A370 was more potent than BIM23A387 (p<0.001). These findings show that SS/D chimeras can inhibit CALU-6 proliferation in an IGF-independent manner, and suggest that this enhanced potency might be due the induction of SSR/DR dimerization. CALU-6 cell line, constitutively expressing SSR and DR, provides a suitable model to elucidate the mechanism of action of SSA and DA upon regulation of cell growth, and to characterize the interaction between SSR and DR.




This article has been cited by other articles:


Home page
 J Mol EndocrinolHome page
D. Ferone, F. Gatto, M. Arvigo, E. Resmini, M. Boschetti, C. Teti, D. Esposito, and F. Minuto
The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology
J. Mol. Endocrinol., May 1, 2009; 42(5): 361 - 370.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
T. Florio, F. Barbieri, R. Spaziante, G. Zona, L. J Hofland, P. M van Koetsveld, R. A Feelders, G. K Stalla, M. Theodoropoulou, M. D Culler, et al.
Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study
Endocr. Relat. Cancer, June 1, 2008; 15(2): 583 - 596.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
D. Ferone, A. Saveanu, M. D Culler, M. Arvigo, A. Rebora, F. Gatto, F. Minuto, and P. Jaquet
Novel chimeric somatostatin analogs: facts and perspectives
Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S23 - S28.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
D. Ferone, R. Pivonello, E. Resmini, M. Boschetti, A. Rebora, M. Albertelli, V. Albanese, A. Colao, M. D Culler, and F. Minuto
Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas
Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S37 - S43.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
D. O'Toole, A. Saveanu, A. Couvelard, G. Gunz, A. Enjalbert, P. Jaquet, P. Ruszniewski, and A. Barlier
The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies
Eur. J. Endocrinol., December 1, 2006; 155(6): 849 - 857.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L. Bodei, G. Paganelli, and G. Mariani
Receptor Radionuclide Therapy of Tumors: A Road from Basic Research to Clinical Applications
J. Nucl. Med., March 1, 2006; 47(3): 375 - 377.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.